SandboxAQ is collaborating with the University of Dundee in the UK to improve its inhibitor for the gene most commonly associated with Parkinson's disease (PD). The company has signed a $25 million research grant through The Michael J Fox Foundation for Parkinson's Research (MJFF) LRRK2 Investigative Therapeutics Exchange (LITE) programme. The research partners aim to […]

To read this content in full, you need to login.

Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!